Renova Therapeutics Stock

renovatherapeutics.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $47.33MM

Renova Therapeutics is the developer of a portfolio of definitive gene and peptide therapies to restore health to people suffering from cardiovascular and metabolic diseases.

Register for Details

For more details on financing and valuation for Renova Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Renova Therapeutics.

Register Today

Team

Management Team

Richard McCloskey MD
Executive Vice President, Clinical Development
Roy Cosan
Board Member & President
Craig Andrews JD
Co-Founder, Board Member and Secretary
Catherine Bovenizer
Chief Financial Officer
Jack Reich Ph.D
Co-Founder, Chief Executive Officer & Board Member
Jennifer Spinella
Executive Vice President of Regulatory Affairs and Quality Assurance

Board Members

Andy Noorda
Kirk Hammond MD
Craig Andrews JD
Roy Cosan
Daniel Bradbury
Biobrit
Michael Torres
Jack Reich Ph.D

Other companies like Renova Therapeutics in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Renova Therapeutics announces Delaware reincorporation
/PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic...
CEO and Co-Founder of Renova Therapeutics receives Entrepreneur of the Year award from Washington & Jefferson College
Updated on: Sep 24, 2023